Post-COVID-19 vaccination and thyrotoxicosis (ASIA Syndrome): Single-Centre experience from india with review of literature

Abstract

Introduction: Thyrotoxicosis is not uncommon after immunization. It is known as 'autoimmune/autoinflammatory syndrome by adjuvants (ASIA syndrome)' and is caused by immunological reaction to adjuvants. However, there is insufficient information on thyrotoxicosis after COVID-19 vaccination in the Indian subcontinent. Aims/Objectives: To investigate the spectrum of thyrotoxicosis after COVID-19 immunization. Settings and Design: A single-centre retrospective study was conducted at a tertiary care academic institute in India. Materials and Methods: We studied the clinical symptoms, biochemical markers, imaging characteristics and treatment of every patient who was diagnosed with thyrotoxicosis within 60 days of receiving the COVID-19 vaccine. Results: Following COVID-19 vaccination, we diagnosed ten people (mean age 39.9 years, range 22-63 years) with thyrotoxicosis [Graves' disease (GD, n-6) and subacute thyroiditis (SAT, n-4)]. The typical duration for symptoms to appear was 2 to 60 days. The majority of patients (n-9) received the COVISHIELDTM vaccine, whereas only one received the COVAXIN® vaccine. After vaccination, two patients with GD developed mildly severe Graves' orbitopathy, with symptoms emerging two days and sixty days later, respectively. Anti-thyroid drugs (methimazole or carbimazole) were required for all GD patients. All SAT patients were treated conservatively with nonsteroidal anti-inflammatory medications and had positive outcomes. Conclusions: SAT, GD and GO may occur as a manifestation of ASIA syndrome, following immunization with COVISHIELDTM and COVAXIN®. Despite the obvious benefits of the COVID-19 vaccine, clinicians should be aware of any potential autoimmune and inflammatory thyroid problems.

Keywords

• asia syndrome
• autoimmune/autoinflammatory syndrome by adjuvants
• covid-19
• graves' disease
• subacute thyroiditis
• thyrotoxicosis
• vaccination